Dr. C. Thirunavukkarasu
About
Research Area
I have been trained in the leading Thomas E Starzl, Transplantation Institute, University of Pittsburgh, PA, USA under renowned hepatologist Prof. CR. Gandhi. The institute is named based on the scientist Prof. Starzl who successfully carried out the first human liver transplantation. My thirst in higher learning and eagerness to get trained under Prof. S. Gupta made me to land in Albert Einstein College of Medicine of Yeshiva University, Newyork, USA. After gaining rich experiences from the renowned institute and the eminent scientists my research area fixates on combating liver diseases, such as hepatocarcinogenesis, liver tumor niche, fatty liver disorders, and hepatotoxicity, employing nanotechnology and biotechnological approach. My contributions have rewarded me the awards from recognized, reputed and prestigious academic bodies/societies. My passion towards teaching starts from foundation course such as “Cell Biology” to advanced level emphasizing the needs of the diseases free society such as “Cancer Biology”. With ample experience, I am a sedulous fervent researcher and believes in strenuous exertion rather than fortuity.
Notable & Recent Publications
Mir IH, Aswathy SA, Guha S, Mohanty AK, Kumar MS, Sujatha V, Ramesh T, Thirunavukkarasu C. Elucidation of 7,8-dihydroxy flavone in complexing with the oxidative stress-inducing enzymes, its impact on radical quenching and DNA damage: An in silico and in vitro approach. Journal of Biomolecular Structure & Dynamics. 2024. 42(8): 4048-4063. Doi: 10.1080/07391102.2023.2218932. (IF 5.235).
Mir IH, Thirunavukkarasu C. The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: Current scenario and anticipated trends (Review). Archives of Toxicology. 2023; 97(8): 2069-2087. (IF 6.168) Doi: 10.1007/s00204-023-03529-w.
Guha S, Sesili S, Mir IH, Thirunavukkarasu C. Epigenetics and mitochondrial dysfunction insights into the impact of the progression of non-alcoholic fatty liver disease. (Review). Cell Biochemistry and Function. 2023; 41(1):4-19. (IF 3.963) DOI: 10.1002/cbf.3763
Nithyananthan S and Thirunavukkarasu C. Arsenic trioxide, a cancer chemo drug hamper fibrotic liver regeneration by interrupting oxidative stress rekindling and stellate cell rejuvenation. Journal of Cellular Physiology. 2020: 235; 1222-1234. (IF 6.384)
Nithyananthan S and Thirunavukkarasu C. Chemotherapeutic doses of arsenic trioxide delays hepatic regeneration by oxidative stress and hepatocyte apoptosis in partial hepatectomy rat. Toxicology and Applied Pharmacology. 2019; 382:114760. (IF 3.347)
